Kyverna Therapeutics named Nadia Dac as chief commercial officer, effective May 4, 2026, as the company moves closer to a first potential approval for miv-cel in stiff person syndrome.
Dac brings more than 30 years of commercial leadership across neurology and rare disease. At Omeros, she built and led the commercial organization for rare disease programs and helped launch Yartemlea, the first FDA-approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy. Before that, she led the launch of Vyepti at Alder Biopharmaceuticals. Her background also includes senior commercial roles at AbbVie, Novartis, Biogen, Pfizer, Johnson & Johnson and Eli Lilly.
Kyverna said Dac will lead commercial strategy and execution for miv-cel, also known as KYV-101, which the company expects to be its first approved treatment for stiff person syndrome, with expansion planned into other neuroimmunology diseases.
As part of her hiring package, Kyverna will grant Dac an option to buy 300,000 shares of common stock. The award vests over four years, with 25% vesting on the one-year anniversary of her start date and the remaining shares vesting monthly afterward.
The appointment comes as Kyverna advances miv-cel through its registrational program. The company said the therapy has already shown potential in multiple indications, including stiff person syndrome and generalized myasthenia gravis, while its broader pipeline includes investigator-initiated and other clinical trials in multiple sclerosis and rheumatoid arthritis. Today the company's shares have moved 1.23% to a price of $9.06. Check out the company's full 8-K submission here.
